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ABSTRACT 
Objective: The present research work was directed towards the synthesis characterization and quantitation of regioisomeric impurity of 
Nimodipine i.e. diethyl 1, 4-dihydro-2,6-dimethyl pyridine dicarboxylate in bulk and tablet formulation, by UV,IR,NMR and GC-MS techniques and a 
RP-HPLC method was developed as per ICH Q2B guidelines for quantitation of 1, 4-Dihydro-2, 6-Dimethyl-4-(p-nitro phenyl) pyridine-3,5 
dicarboxylate (NI) from bulk and formulation.  
Methods: The synthesis of NI was carried out by Hantzch pyridine synthesis, by using p-nitrobenzaldehyde, ethylacetoacetate, in presence of 
ammonia and methanol as a catalyst. The percentage yield was found to be 89.29%. Recrystallization and purification of NI was done. The 
preliminary evaluation was done on laboratory scale via melting point, elemental analysis and TLC.  
Results: The melting point of impurity was found to be 156-1580C. The TLC of impurity was carried by using Chloroform: Methanol (9:1) and the Rf 
was found to be 0.79. The confirmation of structure of NI was carried out by using sophisticated techniques i.e., FT-IR, NMR (13C and 1
Conclusion: The validated optimized method was found to be linear, précised, robust, rugged and accurate. Finally NI was quantified from bulk 
Nimodipine and its marketed tablet formulation. It was concluded that the amount of NI, present in tablet was found to be 0.1% and in the bulk 
0.067% respectively. Thus it was revealed that the NI was found to be within the limit laid down ICH guidelines (Not more than 0.1 %).  
H), GC-MS etc. 
The RP-HPLC method was developed to quantify the NI in Nimodipine bulk and formulation as per ICH Q2B guidelines. The method validation was 
done as per ICH guidelines.  
Keywords: NI, IR, NMR, GCMS, RP-HPLC, Validation. 
 
INTRODUCTION 
Nimodipine is known as Isopropyl 2-methoxy ethyl 1,4- Dihydro 2, 
6-dimethyl-4-(3-nitrophenyl) pyridine -3, 5-dicarboxylate, 
chemically [1]. It is a calcium channel antagonist of the 1, 4-
dihydropyridine class and has been widely used for the treatment of 
hypertension, arrhythmias and angina pectoris, etc. During the 
manufacturing process of an active pharmaceutical substance or 
product, some intermediates are formed. These intermediates may 
affect the safety and efficacy issues of the pharmaceutical products. 
[2, 3] The current research is directed towards the impurity profiling 
of drugs and marketed formulations. [4] Now days the topic gains the 
most importance as compared to the purity of drugs and 
formulations.[3] Qualification of the impurities is the process of 
acquiring and evaluating data that establishes biological safety of an 
individual impurity; thus, revealing the need and scope of impurity 
profiling of drugs in pharmaceutical research.[5,6] As per ICH, 
Impurity profiling is a group of analytical activities, having aim of 
isolation, structure elucidation, identification and quantitative 
determination of organic and inorganic impurities and residual 
solvents in bulk drugs & pharmaceutical formulations.[7,8] Impurity 
is any component of the drug substance or product that is not the 
chemical entity of it, or is any substance coexisting with the original 
drug, like starting materials or intermediates or that is formed, due 
to any side reactions[2].Impurities are unwanted chemical that 
remains within the formulation or API in small amounts which may 
influence quality, safety and efficacy, thereby causing serious health 
hazards. [8] Identification of impurities is done by a variety of 
Chromatographic and spectroscopic techniques, alone or in 
combination with another technique. There are various methods for 
detecting and characterizing impurities with TLC or HPTLC or HPLC 
etc. The pharmacopoeias, such as the Indian Pharmacopoeia (IP), 
British Pharmacopoeia (BP) and the United States Pharmacopoeia 
oflevelsallowabletolimitsincorporatingslowlyare(USP),
impurities present in the APIs or formulations.[3,5,9] Also, the ICH has 
[ICH,published guidelines on impurities in new drug substances
Q3A], products [ICH, Q3B], and residual solvents [ICH, Q3C].[3,4,7,10] 
According to ICH guidelines on impurities in new drug products, 
identification of impurities less than 0.1% level is not considered to 
betoexpectedareimpuritiespotentialunlessnecessary,be
unusually toxic or potent.[10] According to ICH, the maximum daily 
dose qualification threshold is considered as follows; ≤ 2g/day 0.1% 
or 1 mg per day intake (whichever is lower) ≥ 2g/day 0.05% [5,6,7].It 
assures identity, strength, purity, efficacy, safety and quality of drug 
products.andsubstances [2] impuritiesrelatedStereochemistry
includes regioisomeric impurities. These are having similar chemical 
structure but different spatial orientation and are stereo isomers in 









Fig. 1: 1, 4-Dihydro-2, 6- Dimethyl-4-(p- nitro phenyl) pyridine-
3, 5 dicarboxylate 
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MATERIALS AND METHODS 
Chemicals  
P-nitrobenzaldehyde (AR), Ethylacetoacetate (AR), Ammonia (AR), 
Methanol (AR), Acetonitrile (HPLC grade), Methanol (HPLC grade), 
Water (HPLC grade) were purchased from Merck Chemicals, India. 
Instruments 
UV-Visible Spectrophotometer 
The UV detection at wavelength 280 nm was selected by using UV-
Vis Spectrophotometer (UV-1650 PC) SHIMADZU INC. 
FT-IR  
The IR spectra were recorded by using Fourier Transform Infrared 
Spectrophotometer Model No. 8400S SHIMADZU by KBr press pellet 
technique. KBr was purchased from Merck Chemicals, India and was 
AR Grade. 
NMR  
Characterization of impurities was achieved by using Varian NMR 
Mercury 300 MHz spectrometer, using DMSO-d6 as a solvent and 
TMS as an internal reference standard for the proton experiment. All 
experiments were conducted at 25°C, and no shift relaxation agents 
were employed. The 1H and 13
 
Fig. 2: Scheme for the Synthesis of NI 
C NMR chemical shift values were 
reported on the δ scale in ppm. 
GC-MS 
The Q-TOF Micro mass (YA-105) spectrometer capable of recording 
High Resolution Mass Spectrum (HRMS) both in atomic pressure 
chemical ionization (APCI) and Electron spray Ionization (ESR) were 
used for characterization of NI. 
Synthesis of NI 
RP-HPLC  
The HPLC method was developed by using LC20AD Prominence 
Liquid Chromatography SPD 20-A Schimadzu, Japan. The UV-Vis 
detector and C18 column with dimension on 250x 4.6 mm was used 
for the HPLC method development having flow rate of 1.0 ml/min at 
wavelength 280 nm. 
The Methanol: Acetonitrile: Water in proportion of (35:38:27 v/v/v) 
as a mobile phase was selected for development of validated method 
of NI and various parameters according to ICH guidelines (Q2B) 
were studied.
 
Synthesized NI Impurity 
 
0.01 mole (1.52 gm) of p-nitrobenzaldehyde & 0.02 moles (2.60 ml) 
of ethylacetoacetate were added in round bottom flask. Then 5 ml of 
ammonia and 10 ml of methanol was added and was stir vigorously. 
Refluxed for 3 hrs and the solution was poured in cold water and 
was kept for overnight in freezer. Filtered at vacuum filter and 
recrystallized from Methanol. 
Chromatographic Conditions  
Preparation of Mobile phase 
The selection of mobile phase was according to polarity and non-
polarity of solvents. The methanol: acetonitrile: water was selected 
as mobile phase in ratio of 35:38:27(v: v: v) and was filtered on 
membrane filter (0.45 μ) to remove degassing and were stirred for 
15-20 min. 
Preparation of Stock Solution  
The stock solution of 100ug/ml was prepared by dissolving 10 mg 
NI in 100 ml mobile phase. The dilution was prepared in various 
concentrations using stock solution and was dissolved in mobile 
phase. 
Preparation of Sample Solution (Formulation)  
 [10] 
 
The sample solution of Nimodipine formulation was prepared as 
100ug/ml stock solution for quantification of NI in Nimodipine 
formulation. The dilution was prepared in various concentrations 
using sample stock and was dissolved in mobile phase for 
quantification of NI in Nimodipine formulation. 
 
RESULTS AND DISCUSSION 
Physicochemical Properties:  
Table 1: Physicochemical Properties of NI 
Molecular Formula Molecular Weight M.P.0 Rf Value C % Yield 















      NI
2-methoxy ethyl
acetoacetate                     p-nitrobezaldehyde
Reflux for 5-6 hr.Methanol
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UV Spectrum
The λmax of NI in methanol was found to be 280 nm (1) n-π
 [13] 
* transitions. Another peak appears at 239 nm (2) π-π*
  
 transitions. 
A                                       B 
 
C 
Fig. 3: UV Spectrum of A-NI and B-Nimodipine C-Overlay of NI and Nimodipine 
 
IR Data
The major functional groups are primary amine, nitro and carbonyl 
groups. Obtained peaks in IR spectrum are as follows. 
 [13, 14] 
IR (KBr) cm-1: 3400-3200 (NH- Stretch), 3150-2900(C-H Stretch), 
1704(C=O Stretch), 1600-1475(C=C Stretch), 1550-1482(N-O 
Stretch), 1450-1375(CH3 Bend), 1360-1320(NO2
 
 stretch), 900-
700(Oop), 840(Substitution at para position to benzene ring). 
Fig. 4: IR Spectrum of NI 
NMR Data [14, 15] 
1
δ=9 (s,1H,NH of 1,4-dihydropyridine), 8.108 (s,6H,CH
H NMR (DMSO) 
3 of 1,4-
dihydropyridine), 7.44 (q,4H,CH2 proton of ester), 5.01 (t,6H,,CH3 
proton of ester), 4.01 (s,1H attached to1,4-dihydropyridine ring), 
2.301 (d,2H, CH attached to nitrobenzene ring), 1.142 (d,2H,CH 
attached to nitrobenzene ring). 1
 
H NMR Spectrum of NI was 
recorded and is shown below. 
Fig. 5: 1H NMR Spectrum of NI 
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13
δ=14.062,(2C, CH3 Carbon attached to CH
C NMR (DMSO)  
2),59.169(2C,CH2 Carbon 
attached to CH3),166.5(2C, Carbonyl carbon attached to 1,4- 
dihydropyridine ring), 18.188(2C,CH3 Carbon attached to 1,4- 
dihydropyridine ring),146.265(2C, CH2=CH2 of 1,4- dihydropyridine 
ring),100.838(2C, CH2=CH2 of 1,4- dihydropyridine ring),40(1C, 
Carbon attached to 1,4- dihydropyridine),155.48(1C, Carbon 
attached to nitrobenzene ring),128.566(2C,CH Carbon attached to 
meta position of p-nitrobenzene ring),123.208 (2C, CH Carbon 
attached to ortho position of p-nitrobenzene ring),145.796(1C, 
Carbon attached to nitrobenzene ring). 
13
 
C NMR Spectrum of NI was recorded and is shown below. 
Fig. 6: 13
 
C NMR Spectrum of NI. 
GC-MS Data
 
 [11, 12] 
Fig. 9: GC of NI 
Gas Chromatogram of NI shows a single peak at 28.9 min.which 
indicates purity of synthesized NI. Mass spectrum at 28.9 min was 
recorded and is given below. Peak appear at 374 indicates presence 
of molecular ion peak. Major base peak at 252 shows 100% 
abundance. Peak at 252 appear due to elimination of C6H4-NO2
 
. GC 
Chromatogram of NI showed a single peak at 28.9 min.  
Fig. 8: Mass Spectrum of NI 
Mass Fragmentation Pattern 
Mass fragmentation pattern for NI is decided from mass spectrum 
obtained at retention time 28.9 minutes and is shown below. 
 
 
Fig. 7: Mass Fragmentation Pattern of NI 
 
HPLC Method Development
Validation experiment was performed to demonstrate system 
suitability, linearity, precision, accuracy study, ruggedness and 
robustness as per ICH Q2B guidelines. 
 [16] 
System Suitability Parameters 
The area of respective concentrations, theoretical plates, number of 
theoretical plates per cm, Tailing factor and the peak symmetry was 
recorded. 
Linearity 
Dilution of standard impurity in the range of 400-1400 ng/ml were 
prepared by taking suitable aliquots of working standard solution in 
different 10 ml volumetric flasks and diluting up to the mark with 
mobile phase. 20 µl was injected from it each time on column at flow 
rate of 1 ml/min. The standard from elute was monitored at 280 nm 
and corresponding chromatogram were obtained from these 
chromatograms peak area were calculated. A plot of peak area over 
concentration was constructed. Regression of the plot was computed 
by least square regression method. 
Precision 
Precision of analytical method was studied by multiple injections of 
homogenous samples. 6 replicate of 800 ng solution were prepared 
and injected for precision at the same flow rate of 1ml/min. The 
intra-day, inter-day and intermediate precision were used to study 
the variability of the method. S.D. and % R.S.D. were calculated for 
both. 
Accuracy  
Accuracy of the method was studied using the method of standard 
addition. Standard impurity solutions were added to the unknown 
bulk and tablet formulation of Nimodipine. The percent recovery 
was determined at three different levels (50%, 100% and 150%). 
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Robustness 
Robustness was studied by changing parameters like change in flow 
rate. The S.D. and % R.S.D. between the change parameter were 
calculated. 
Ruggedness 
Ruggedness was studied was carried out by using different analysts. 
The S.D. and % R.S.D. were calculated. 
LOD and LOQ 
Limit of detection and limit of Quantitation of the method was 
calculated by formula given below 
LOD= 3.3xS.D./Slope 
LOQ= 10xS.D./Slope 
Quantitation of NI 
The total amount of impurity present in Nimodipine bulk and 
formulation was calculated for the NI and the result was compared 
to ICH limit for impurities in new drug substance and products is 
0.1%.
 
Fig. 10: HPLC Chromatogram of Nimodipine 
[3,17] 
HPLC Chromatograms 
HPLC Chromatogram of Nimodipine 
HPLC Chromatogram of Nimodipine was recorded and is shown below. 
 
The Retention time of Nimodipine was 9.280 min. 
 
HPLC Chromatogram of NI 
HPLC Chromatogram of NI was recorded and is shown below 
 
Fig. 11: HPLC Chromatogram of NI 
The retention time of NI was 10.343 min and it shows a single peak 
which indicates purity of compound. 
 
HPLC Chromatogram of Nimodipine and NI Combination 
HPLC Chromatogram of Nimodipine and NI combination was 
recorded and is shown below. 
 
 
Fig. 12: HPLC Chromatogram of Nimodipine and NI Mixture 
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The retention time of Nimodipine and NI in laboratory mixture was 
found at 9.260 min and 10.167 min respectively. 
 
HPLC Chromatogram of Tablet 
HPLC Chromatogram of Nimodipine tablet was recorded and is 
shown below. 
 
Fig. 13: HPLC Chromatogram of Nimodipine Tablet 
 
 
 The retention time of Nimodipine and NI in tablet was found at 
9.477 min. and 10.423 min. respectively. 
 
HPLC Chromatogram of Tablet and NI Mixture 
HPLC Chromatogram of Nimodipine tablet and NI was recorded and 
is shown below. 
 
Fig. 14: HPLC Chromatogram of Tablet and NI Mixture 
 
 
The retention time of Nimodipine in Tablet and NI in laboratory 
mixture was found at 9.527 and 10.480 min respectively. 
a. Linearity 
 
Fig. 15: Calibration Curve of NI 
 
Table 2: Linearity Data of NI 
S. No. Parameter Observation 
1. Linearity Range 400-1400 ng/ml 
2. Slope 31.49 
3. Intercept -1.967 
4. Correlation Coefficient 0.9962 
5. LOD 7.545 ng/ml 
6. LOQ 22.86 ng/ml 
 
b. Repeatability 
Table 3: Results of Repeatability Studies 
S. No. Parameter S.D. %R.S.D. 
1. Precision 0.07141 0.2999 
2. Intraday Precision 
(After 4 Hrs.) 
0.1306 0.5445 
3. Interday Precision 
(After 24 Hrs.) 
0.2711 1.0577 
4. Intermediate Precision 0.0908 0.2891 
5. Robustness 
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c. Accuracy 
Table 4: Results of Recovery of NI 






2000 1000 950 
2000 2000 1930 





2000 1000 960 
2000 2000 1940 
2000 3000 2950 
 
Table 5: Results of Accuracy Studies 
S. No. Drug / Formulation Percentage Recovery Mean S.D. %R.S.D. 
50% 100% 150% 
1. Bulk 95.98 96.70 97.23 96.63 0.6274 0.6493 
2. Tablet  95.50 97.32 98.25 97.36 0.8756 0.8993 
  
d. System Suitability Parameters 
Table 6: System Suitability Parameters 
S. No. Property Values Official Limits 
1. Retention time(tR 10.343 min ) - 
2. Theoretical Plates(N) 8744 N ≥ 2000 
3. Resolution(R) 2.280 R ≥ 2 
4. Tailing Factor(T) 0.98 T ≤ 2 
 
e. Summary of Retention time and Asymmetry 
Table 7: Summary of Retention Time and Asymmetry 
S. No. Compound Retention Time (Min.) Asymmetry 
1. Nimodipine 9.280 1.152 
2. NI 10.343 1.155 
3. Nimodipine Tablet 9.477 1.063 
 
f. Quantitation of NI 
Table 8: Quantitation of NI in Bulk and Tablet 
S. No. Bulk/Formulation Quantitation of NI 
1. Bulk Nimodipine 0.0672% 
2. Nimodipine Tablet 0.1% 
 
Thin Layer Chromatography (TLC) 
The Mobile phase Chloroform: Methanol (9:1 v/v)  
Rf
(Iodinated) (Plane) 
 Value = 0.79  
 
Fig. 16: TLC of NI 
CONCLUSION 
The regioisomeric impurity of Nimodipine diethyl 1, 4-dihydro-2, 6-
dimethyl pyridine 3, 5 dicarboxylate in bulk and formulation was 
synthesized, characterized and the RP-HPLC method was developed 
according to ICH Q2B guidelines for quantitation of NI from 
Nimodipine bulk and tablet formulation. The synthesis of NI was 
carried out by Hantzch pyridine synthesis. The % yield was found to 
be 89.29%. The preliminary evaluation was done on laboratory scale 
viz. melting point, TLC and elemental analysis. The melting point of 
NI was found to be 156-1580C. The TLC of NI was carried by using 
Chloroform and Methanol (9:1) and the Rf was found to be 0.79.The 
confirmation of structure of NI was carried out by using 
sophisticated instruments viz, FT-IR, NMR (1H and 13 C), GC-MS.A RP-
HPLC method was developed to identify and quantify the NI from 
Nimodipine bulk and formulation, as per ICH Q2B guidelines. The 
method was found to be linear, precise, robust, rugged and accurate. 
Finally NI was quantified from bulk Nimodipine and its marketed 
tablet formulation. It was observed that the amount of NI, diethyl 1, 
4-dihydro-2, 6-dimethyl-4(p-nitro phenyl) pyridine-3, 5-
dicarboxylate present in tablet was found to be 0.1 % and in bulk 
drug, it was found to be 0.0672 %. Thus it was found that the 
impurity was found to be within the limit laid down as per ICH 
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guidelines (not more than 0.1 %). Thus impurity profiling can act as 
a quality Control tool. 
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